Compare Figure Technology Solutions Inc. Class A Common Stock (FIGR) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figure Technology Solutions Inc. Class A Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $28.04 (market cap $6.19B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.91 (market cap $6.04B). The key difference: Figure Technology Solutions Inc. Class A Common Stock and Iovance Biotherapeutics Inc. Common Stock are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Figure Technology Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| FIGR | IOVA | |
|---|---|---|
Market Cap | $6.19B | $6.04B |
Volume | 4,762,342 | 14,805,993 |
Sector | Financials | Health |
52-Week High | $73.91 | $14.82 |
52-Week Low | $24.91 | $1.81 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.23B | $5.97B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figure Technology Solutions Inc. Class A Common Stock
Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.
Read more on FIGR →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
